Shots:
- Genentech has reported new data from the open-label AVONELLE-X & P-IIIb/IV (SALWEEN) studies of Vabysmo (faricimab-svoa) at Euretina’25
- The 2yr. AVONELLE-X study was an extension of P-III (TENAYA & LUCERNE) trials, showing maintained vision & anatomy in wet AMD, with ~80% pts extending dosing to Q3M/Q4M after ~4yrs. of therapy
- SALWEEN study in Asia showed Vabysmo led to a mean +8.9 letter gain in BCVA averaged over wks. 40, 44 & 48, with >60% pts showing complete resolution of PCV lesions & 86% achieving lesion inactivation by 1yr.; >50% pts were extended to 5mos. dosing. Vabysmo was well tolerated across both studies
Ref: Genentech| Image: Genentech| Press Release
Related News:- Genentech Reports P-II (FENopta) Trial Data of Fenebrutinib for Relapsing Multiple Sclerosis (RMS)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
